Cover Image
市場調查報告書

無菌醫療包裝市場上法規環境、影響分析 2020年:規格 & 法規,地區 & 該國法規團體

Regulatory Environment and Impact Analysis - Sterile Packaging Market Standards & Regulations, Regional & National Regulatory Bodies - Market Analysis & Forecast to 2020

出版商 MarketsandMarkets 商品編碼 356410
出版日期 內容資訊 英文 124 Pages
訂單完成後即時交付
價格
Back to Top
無菌醫療包裝市場上法規環境、影響分析 2020年:規格 & 法規,地區 & 該國法規團體 Regulatory Environment and Impact Analysis - Sterile Packaging Market Standards & Regulations, Regional & National Regulatory Bodies - Market Analysis & Forecast to 2020
出版日期: 2016年04月15日 內容資訊: 英文 124 Pages
簡介

全球無菌醫療包裝市場,預計從2015年的265億5,000萬美元到2020年達到350億7,000萬美元,最近的年複合成長率 (CAGR) 預計為5.72% 。

本報告提供全球無菌醫療包裝市場調查,市場概要,國際的法規團體,地區、主要國家的市場規模主要的法規團體,及主要法規等相關分析。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 無菌醫療包裝的市場概要

  • 簡介
  • 發展
  • 市場動態
    • 促進要素
    • 抑制因素
    • 機會
    • 課題
  • 無菌醫療包裝的開發
  • 無菌醫療包裝的功能
    • 保護
    • 可用性
    • 識別
    • 流程可能性
    • 特殊用途

第5章 國際法規團體

  • 簡介
  • 美國實驗材料協會 (ASTM)
  • 國際標準化組織 (ISO)
  • 美國食品藥物管理局 (FDA)
  • 國際醫療設備法規當局論壇 (IMDRF)

第6章 北美無菌醫療包裝的法律規範

  • 北美
  • 北美的無菌醫療包裝市場規模:各國
    • 美國
    • 美國主要的法規團體
    • 加拿大
    • 加拿大主要的法規團體
    • 墨西哥
    • 墨西哥主要的法規團體

第7章 歐洲的無菌醫療包裝的法律規範

  • 歐洲
  • 歐洲的無菌醫療包裝市場規模:各國
  • 歐洲的法規團體
    • 歐洲標準化委員會 (CEN)
    • STERILE BARRIER ASSOCIATION (SBA)
  • 歐洲的醫療設備法規
    • 簡介
    • 醫療設備指令 (93/42/EEC)
  • 歐洲的醫療設備法規的影響
    • CE標註:進入歐洲市場的入口
    • EN和ISO間的協調的影響
  • 歐洲的主要國家
    • 德國
    • 德國主要的法規團體
    • 英國
    • 英國的主要法規團體
    • 法國
    • 法國主要的法規團體
    • 義大利
    • 義大利主要的法規團體

第8章 亞太地區的無菌醫療包裝的法律規範

  • 亞太地區
  • 亞太地區的無菌醫療包裝市場規模:各國
    • 中國
    • 中國主要的法規團體
    • 日本
    • 日本主要的法規團體
    • 印度
    • 印度主要的法規團體
    • 澳洲
    • 澳洲主要的法規團體

第9章 其他 (ROW) 無菌醫療包裝的法律規範

  • ROW
  • ROW的無菌醫療包裝市場規模:各國
    • 巴西
    • 巴西主要的法規團體
    • 阿根廷
    • 阿根廷主要的法規團體
    • 南非
    • 南非主要的法規團體

第10章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PK 4234

Growing demand from the healthcare industry to drive the market for sterile medical packaging

The global market for sterile medical packaging is projected to grow from USD 26.55 billion in 2015 to reach USD 35.07 billion by 2020, at an estimated CAGR of 5.72%. The market for sterile medical packaging is driven by the growing demand from the healthcare industry due to increase in health awareness.

Need for harmonization between the global standards and regulations in the sterile medical packaging market

In line with the global applicable standards, each country may have its own specific set of applications and environments in which the product needs to perform. Having multiple standards may create confusion and trade barriers for manufacturers. Hence, in order to avoid this as well as to easily understand and implement packaging requirements, harmonization between the standards is necessary.

Asia-Pacific projected to grow during the forecast period

Asia-Pacific is projected to be the fastest-growing region in the sterile medical packaging market in the next five years. However, factors such as longer timelines for approving the medical devices in Australia, red tapism in India, and higher cost for the approval of medical devices make the regulatory framework in the region more complex.

Breakdown of Primaries:

Primary interviews were conducted with a number of industry experts in order to collect data related to different aspects of sterile medical packaging. Estimates reached after analyzing secondary sources were validated through these interviews. Primary sources include professionals such as sterile packaging manufacturers, distributors, and academic professionals. Distribution of primary interviews is as follows:

  • By Company Type: Tier 1 - 38%, Tier 2 - 38%, and Tier 3 - 24%
  • By Designation: C-level - 38%, Manager Level - 34%, and Others* - 28%
  • By Region: North America - 32%, Europe - 28%, Asia-Pacific - 25%, and RoW - 15%

The tier of the companies is defined on the basis of their total revenue, as of 2014: Tier 1: Revenue over USD 500 million, Tier 2: Revenue USD 100 to USD 500 million, and Tier 3: Revenue Less than USD 100 million.

Others include sales managers, marketing managers, and product managers.

Reasons to Buy the Report:

The report will help the market leaders/new entrants in this market in the following ways:

  • 1. This report segments the market for sterile medical packaging comprehensively and provides the closest approximations of the revenue numbers for the overall market across different regions.
  • 2. The report helps stakeholders to understand the market and related regulations further providing them information on key market drivers, restraints, challenges, and opportunities.
  • 3. The report helps to understand the regulatory aspects of the sterile medical packaging industry for the top key countries and regions.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. STUDY SCOPE
    • 1.3.1. PERIODIZATION CONSIDERED FOR THE STERILE MEDICAL PACKAGING MARKET
  • 1.4. CURRENCY CONSIDERED FOR THE STERILE MEDICAL PACKAGING MARKET
  • 1.5. UNIT CONSIDERED FOR THE STERILE MEDICAL PACKAGING MARKET
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH DATA
    • 2.1.1. SECONDARY DATA
      • 2.1.1.1. Key Data From Secondary Sources
    • 2.1.2. PRIMARY DATA
      • 2.1.2.1. Key Data From Primary Sources
        • 2.1.2.1.1. Breakdown of primaries by company type, designation & region
  • 2.2. FACTOR ANALYSIS
    • 2.2.1. INTRODUCTION
    • 2.2.2. OVERVIEW OF PARENT INDUSTRY
    • 2.2.3. DEMAND-SIDE ANALYSIS
      • 2.2.3.1. Rising Population
        • 2.2.3.1.1. Increase in the middle-class population, 2009-2030
      • 2.2.3.2. Increasing Urban population
      • 2.2.3.3. Developing Economies: GDP (Purchasing Power Parity)
    • 2.2.4. SUPPLY-SIDE ANALYSIS
      • 2.2.4.1. Fluctuation in Raw Material Prices
      • 2.2.4.2. Increasing Investment in Research & Development to Develop Innovative Technologies
  • 2.3. MARKET SIZE ESTIMATION
  • 2.4. MARKET BREAKDOWN & DATA TRIANGULATION
  • 2.5. RESEARCH ASSUMPTIONS & LIMITATIONS
    • 2.5.1. ASSUMPTIONS
    • 2.5.2. LIMITATIONS

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. REGULATORY SCENARIO
    • 3.2.1. REGULATORY FRAMEWORK IN NORTH AMERICA
    • 3.2.2. REGULATORY FRAMEWORK IN ASIA-PACIFIC
    • 3.2.3. REGULATORY FRAMEWORK IN EUROPE
    • 3.2.4. REGULATORY FRAMEWORK IN ROW
  • 3.3. MEDICAL DEVICE APPROVAL PROCESS IN KEY COUNTRIES
  • 3.4. IMPACT ANALYSIS
    • 3.4.1. CASE STUDY: MEDICAL DEVICE RECALL & ITS IMPACT
    • 3.4.2. NEED FOR HARMONIZATION OF GLOBAL STANDARDS & REGULATIONS

4. MARKET OVERVIEW OF STERILE MEDICAL PACKAGING

  • 4.1. INTRODUCTION
  • 4.2. EVOLUTION
  • 4.3. MARKET DYNAMICS
    • 4.3.1. DRIVERS
      • 4.3.1.1. Increased Health Awareness
      • 4.3.1.2. Growing Demand from Healthcare Industry
      • 4.3.1.3. Aging Population
    • 4.3.2. RESTRAINTS
      • 4.3.2.1. Stringent Regulations
    • 4.3.3. OPPORTUNITIES
      • 4.3.3.1. New Product Development and Continuous Innovations in Pharmaceuticals
      • 4.3.3.2. Developing New Sustainable Packaging Options
    • 4.3.4. CHALLENGES
      • 4.3.4.1. Maintaining Medical Packaging Integrity
      • 4.3.4.2. Rise in Healthcare Cost
  • 4.4. STERILE MEDICAL PACKAGE DEVELOPMENT
  • 4.5. FUNCTIONS OF A STERILE MEDICAL PACKAGE
    • 4.5.1. PROTECTION
    • 4.5.2. EASE OF USE
    • 4.5.3. IDENTIFICATION
    • 4.5.4. PROCESSABILITY
    • 4.5.5. SPECIAL APPLICATIONS

5. INTERNATIONAL GOVERNING BODIES

  • 5.1. INTRODUCTION
  • 5.2. AMERICAN SOCIETY FOR TESTING AND MATERIALS (ASTM)
    • 5.2.1. ASTM COMMITTEE D10
      • 5.2.1.1. D10.13
      • 5.2.1.2. D10.19
      • 5.2.1.3. D10.27
      • 5.2.1.4. D10.32
    • 5.2.2. ASTM COMMITTEE F02
      • 5.2.2.1. F02.10
      • 5.2.2.2. F02.15
      • 5.2.2.3. F02.20
      • 5.2.2.4. F02.40
      • 5.2.2.5. F02.50
  • 5.3. INTERNATIONAL ORGANIZATION OF STANDARDIZATION (ISO)
    • 5.3.1. DEVELOPING ISO STANDARDS
      • 5.3.1.1. Preliminary Stage
      • 5.3.1.2. Proposal Stage
      • 5.3.1.3. Preparatory Stage
      • 5.3.1.4. Committee Stage
      • 5.3.1.5. Enquiry Stage
      • 5.3.1.6. Approval Stage
      • 5.3.1.7. Publication Stage
    • 5.3.2. STANDARDS RELATED TO STERILE MEDICAL PACKAGING
      • 5.3.2.1. ISO 16775
      • 5.3.2.2. ISO 11607
        • 5.3.2.2.1. Application
        • 5.3.2.2.2. Limitation
      • 5.3.2.3. ISO 11607-1
      • 5.3.2.4. ISO 11607-2
  • 5.4. U.S. FOOD AND DRUG ADMINISTRATION (FDA)
  • 5.5. INTERNATIONAL MEDICAL DEVICE REGULATORY FORUM (IMDRF)

6. REGULATORY FRAMEWORK FOR STERILE MEDICAL PACKAGING IN NORTH AMERICA

  • 6.1. NORTH AMERICA
  • 6.2. NORTH AMERICA: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY
    • 6.2.1. U.S.
    • 6.2.2. KEY GOVERNING BODIES IN THE U.S.
      • 6.2.2.1. FDA
        • 6.2.2.1.1. Overview
        • 6.2.2.1.2. Responsibilities
    • 6.2.3. CANADA
    • 6.2.4. KEY GOVERNING BODIES IN CANADA
      • 6.2.4.1. Health Canada (HC)
        • 6.2.4.1.1. Overview
        • 6.2.4.1.2. Responsibilities
    • 6.2.5. MEXICO
    • 6.2.6. KEY GOVERNING BODIES IN MEXICO
      • 6.2.6.1. Federal Commission for the Protection Against Sanitary Risk (COFEPRIS)
        • 6.2.6.1.1. Overview
        • 6.2.6.1.2. Responsibilities

7. REGULATORY FRAMEWORK FOR STERILE MEDICAL PACKAGING IN EUROPE

  • 7.1. EUROPE
  • 7.2. EUROPE: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY
  • 7.3. GOVERNING BODIES IN EUROPE
    • 7.3.1. EUROPEAN COMMITTEE FOR STANDARDIZATION (CEN)
      • 7.3.1.1. Overview
      • 7.3.1.2. Standards Developed by CEN
        • 7.3.1.2.1. Harmonization of EN 868-1 and ISO 11607
        • 7.3.1.2.2. EN 868-2: 2009
        • 7.3.1.2.3. EN 868-3:2009
        • 7.3.1.2.4. EN 868-4:2009
        • 7.3.1.2.5. EN 868-5:2009
        • 7.3.1.2.6. EN 868-6:2009
        • 7.3.1.2.7. EN 868-7:2009
        • 7.3.1.2.8. EN 868-8:2009
        • 7.3.1.2.9. EN 868-9:2009
        • 7.3.1.2.10. EN 868-10:2009
    • 7.3.2. STERILE BARRIER ASSOCIATION (SBA)
      • 7.3.2.1. Overview
      • 7.3.2.2. SBA Member Categories
      • 7.3.2.3. Administering Activities
  • 7.4. MEDICAL DEVICE REGULATIONS IN EUROPE
    • 7.4.1. INTRODUCTION
    • 7.4.2. MEDICAL DEVICE DIRECTIVE (93/42/EEC)
  • 7.5. IMPACT OF MEDICAL DEVICE REGULATIONS IN EUROPE
    • 7.5.1. CE MARKING- A GATEWAY TO ACCESS EUROPEAN MARKET
    • 7.5.2. IMPACT OF HARMONIZATION BETWEEN EN AND ISO
  • 7.6. KEY COUNTRIES IN EUROPE
    • 7.6.1. GERMANY
    • 7.6.2. KEY GOVERNING BODIES IN GERMANY
      • 7.6.2.1. Federal Ministry of Health
        • 7.6.2.1.1. Overview
        • 7.6.2.1.2. Administering activities
      • 7.6.2.2. German Institute for Standardization (DIN)
        • 7.6.2.2.1. Overview
        • 7.6.2.2.2. Organizational structure
        • 7.6.2.2.3. Administering activities
    • 7.6.3. U.K.
    • 7.6.4. KEY GOVERNING BODIES IN THE U.K.
      • 7.6.4.1. Medicines and Healthcare products Regulatory Agency (MHRA)
        • 7.6.4.1.1. Overview
        • 7.6.4.1.2. Responsibilities
      • 7.6.4.2. Department of Health (DH)
        • 7.6.4.2.1. Overview
        • 7.6.4.2.2. Responsibilities
      • 7.6.4.3. Association of British Healthcare Industries (ABHI)
        • 7.6.4.3.1. Overview
        • 7.6.4.3.2. Responsibilities
      • 7.6.4.4. The British Standards Institution (BSI)
        • 7.6.4.4.1. Overview
        • 7.6.4.4.2. Responsibilities
    • 7.6.5. FRANCE
    • 7.6.6. KEY GOVERNING BODIES IN FRANCE
      • 7.6.6.1. National Agency for the Safety of Medicine and Health Products (ANMS)
        • 7.6.6.1.1. Overview
        • 7.6.6.1.2. Responsibilities
    • 7.6.7. ITALY
    • 7.6.8. KEY GOVERNING BODIES IN ITALY
      • 7.6.8.1. Ministry of Health (MOH)
        • 7.6.8.1.1. Overview
        • 7.6.8.1.2. Responsibilities
      • 7.6.8.2. Italian Medicines Agency
        • 7.6.8.2.1. Overview
        • 7.6.8.2.2. Responsibilities

8. REGULATORY FRAMEWORK FOR STERILE MEDICAL PACKAGING IN ASIA-PACIFIC

  • 8.1. ASIA-PACIFIC
  • 8.2. ASIA-PACIFIC: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY
    • 8.2.1. CHINA
    • 8.2.2. KEY GOVERNING BODIES IN CHINA
      • 8.2.2.1. China Food and Drug Administration (CFDA)
        • 8.2.2.1.1. Overview
        • 8.2.2.1.2. Responsibilities
    • 8.2.3. JAPAN
    • 8.2.4. KEY GOVERNING BODIES IN JAPAN
      • 8.2.4.1. Ministry of Health, Labor and Welfare (MHLW)
        • 8.2.4.1.1. Overview
        • 8.2.4.1.2. Responsibilities
    • 8.2.5. INDIA
    • 8.2.6. KEY GOVERNING BODIES IN INDIA
      • 8.2.6.1. Central Drugs Standard Control Organization (CDSCO)
        • 8.2.6.1.1. Overview
        • 8.2.6.1.2. Responsibilities
    • 8.2.7. AUSTRALIA
    • 8.2.8. KEY GOVERNING BODIES IN AUSTRALIA
      • 8.2.8.1. Therapeutic Goods Administration (TGA)
        • 8.2.8.1.1. Overview
        • 8.2.8.1.2. Responsibilities

9. REGULATORY FRAMEWORK FOR STERILE MEDICAL PACKAGING IN ROW

  • 9.1. ROW
  • 9.2. ROW: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY
    • 9.2.1. BRAZIL
    • 9.2.2. KEY GOVERNING BODIES IN BRAZIL
      • 9.2.2.1. National Health Surveillance Agency (ANVISA)
        • 9.2.2.1.1. Overview
        • 9.2.2.1.2. Responsibilities
    • 9.2.3. ARGENTINA
    • 9.2.4. KEY GOVERNING BODIES IN ARGENTINA
      • 9.2.4.1. National Administration of Drugs, Foodstuffs, and Medical Technology (ANMAT)
        • 9.2.4.1.1. Overview
        • 9.2.4.1.2. Responsibilities
    • 9.2.5. SOUTH AFRICA
    • 9.2.6. KEY GOVERNING BODIES IN SOUTH AFRICA
      • 9.2.6.1. Medicines Control Council (MCC)
        • 9.2.6.1.1. Overview
        • 9.2.6.1.2. Responsibilities

10. APPENDIX

  • 10.1. INSIGHTS OF INDUSTRY EXPERTS
  • 10.2. DISCUSSION GUIDE
  • 10.3. INTRODUCING RT: REAL TIME MARKET INTELLIGENCE
  • 10.4. AVAILABLE CUSTOMIZATIONS
  • 10.5. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: ASIA-PACIFIC: URBANIZATION PROSPECTS
  • TABLE 2: TECHNICAL SUBCOMMITTEES
  • TABLE 3: TECHNICAL SUBCOMMITTEES
  • TABLE 4: ANNEX
  • TABLE 5: ISO 11607-1
  • TABLE 6: ISO 11607-2
  • TABLE 7: NORTH AMERICA: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 8: NORTH AMERICA: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 9: EUROPE: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 10: EUROPE: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 11: EN 868-2:2009
  • TABLE 12: IMPLEMENTATION OF EN 868-2:2009 IN EUROPEAN COUNTRIES
  • TABLE 13: EN 868-3:2009
  • TABLE 14: IMPLEMENTATION OF EN 868-3:2009 IN EUROPEAN COUNTRIES
  • TABLE 15: EN 868-4:2009
  • TABLE 16: IMPLEMENTATION OF EN 868-4:2009 IN EUROPEAN COUNTRIES
  • TABLE 17: EN 868-5:2009
  • TABLE 18: IMPLEMENTATION OF EN 868-5:2009 IN EUROPEAN COUNTRIES
  • TABLE 19: EN 868-6:2009
  • TABLE 20: IMPLEMENTATION OF EN 868-6:2009 IN EUROPEAN COUNTRIES
  • TABLE 21: EN 868-7:2009
  • TABLE 22: IMPLEMENTATION OF EN 868-7:2009 IN EUROPEAN COUNTRIES
  • TABLE 23: EN 868-8:2009
  • TABLE 24: IMPLEMENTATION OF EN 868-8:2009 IN EUROPEAN COUNTRIES
  • TABLE 25: EN 868-9:2009
  • TABLE 26: IMPLEMENTATION OF EN 868-9:2009 IN EUROPEAN COUNTRIES
  • TABLE 27: EN 868-10:2009
  • TABLE 28: IMPLEMENTATION OF EN 868-10:2009 IN EUROPEAN COUNTRIES
  • TABLE 29: STANDARDS PUBLISHED BY NA 063-04-04
  • TABLE 30: ASIA-PACIFIC: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 31: ASIA-PACIFIC: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 32: ROW: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 33: ROW: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)

LIST OF FIGURES

  • FIGURE 1: GLOBAL POPULATION PROJECTED TO REACH ?9.5 BILLION BY 2050
  • FIGURE 2: MIDDLE-CLASS POPULATION, 2009-2030
  • FIGURE 3: PROJECTED GDP PER CAPITA, BY COUNTRY
  • FIGURE 4: FLUCTUATIONS IN PRICE OF NATURAL GAS FROM 2008 TO 2015
  • FIGURE 5: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 6: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 7: NORTH AMERICA DOMINATED THE STERILE MEDICAL PACKAGING MARKET IN 2014
  • FIGURE 8: MEDICAL DEVICES APPROVAL PROCESS IN EUROPE
  • FIGURE 9: MEDICAL DEVICES APPROVAL PROCESS IN CHINA
  • FIGURE 10: MEDICAL DEVICES APPROVAL PROCESS IN AUSTRALIA
  • FIGURE 11: PROCESS TO SUPPLY IMPORTED MEDICAL DEVICES IN AUSTRALIA
  • FIGURE 12: MEDICAL DEVICES APPROVAL PROCESS IN JAPAN
  • FIGURE 13: MEDICAL DEVICES APPROVAL PROCESS IN BRAZIL
  • FIGURE 14: REASONS FOR MEDICAL DEVICE PRODUCT RECALLS
  • FIGURE 15: EVOLUTION OF STERILE MEDICAL PACKAGING
  • FIGURE 16: STERILE MEDICAL PACKAGING MARKET DYNAMICS
  • FIGURE 17: REVENUE GENERATED BY PHARMACEUTICALS AND MEDICINES IN THE U.S.
  • FIGURE 18: GLOBAL AGING POPULATION, 2010-2015
  • FIGURE 19: NUMBER OF RECALLS, 2010-2012
  • FIGURE 20: SPENDING ON RETAIL PRESCRIPTION DRUGS
  • FIGURE 21: ISO STANDARDS PORTFOLIO, BY SECTOR, 2014
  • FIGURE 22: DEVELOPMENT PROCESS FOR ISO STANDARDS
  • FIGURE 23: MEDICAL DEVICE CIRCLE
  • FIGURE 24: MEDICAL DEVICES APPROVAL PROCESS BY FDA
  • FIGURE 25: FDA: ORGANIZATION CHART
  • FIGURE 26: HEALTH CANADA: ORGANIZATION CHART
  • FIGURE 27: FEDERAL COMMISSION FOR THE PROTECTION AGAINST SANITARY RISK: ORGANIZATION STRUCTURE
  • FIGURE 28: FEDERAL MINISTRY OF HEALTH: ORGANIZATION CHART
  • FIGURE 29: MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY: ORGANIZATIONAL STRUCTURE
  • FIGURE 30: DEPARTMENT OF HEALTH: ORGANIZATION CHART
  • FIGURE 31: ASSOCIATION OF BRITISH HEALTHCARE INDUSTRIES: ORGANIZATION STRUCTURE
  • FIGURE 32: THE BRITISH STANDARDS INSTITUTION: ORGANIZATION STRUCTURE
  • FIGURE 33: NATIONAL AGENCY FOR THE SAFETY OF MEDICINE AND HEALTH PRODUCTS: ORGANIZATION CHART
  • FIGURE 34: MINISTRY OF HEALTH: ORGANIZATION STRUCTURE
  • FIGURE 35: ITALIAN MEDICINES AGENCY: ORGANIZATION CHART
  • FIGURE 36: MINISTRY OF HEALTH, LABOR AND WELFARE: ORGANIZATION STRUCTURE
  • FIGURE 37: CENTRAL DRUGS STANDARD CONTROL ORGANIZATION: ORGANIZATION STRUCTURE
  • FIGURE 38: THERAPEUTIC GOODS ADMINISTRATION: ORGANIZATION STRUCTURE
  • FIGURE 39: MEDICINES CONTROL COUNCIL: ORGANIZATION STRUCTURE "
Back to Top